The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-06), Clinuvel Pharmaceuticals's share price is $7.30.
Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.42. Therefore, Clinuvel Pharmaceuticals's PE Ratio for today is 17.30.
During the past 13 years, Clinuvel Pharmaceuticals's highest PE Ratio was 144.38. The lowest was 12.48. And the median was 48.81.
During the past 12 months, Clinuvel Pharmaceuticals's average EPS without NRIGrowth Rate was -15.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 21.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 16.60% per year.
During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 13.80% per year.
Clinuvel Pharmaceuticals (OTCPK:CLVLY) PE Ratio Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's PE Ratio falls into.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Clinuvel Pharmaceuticals's Share Price of today is $7.30.
For company reported semi-annually, Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Clinuvel Pharmaceuticals (CLVLY) has a PE Ratio of 17.30 as of Jul. 06, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 65% below median its historical median of 48.81. Over the past decade, Clinuvel Pharmaceuticals' PE Ratio has ranged from 12.48 to 144.38.
Is Clinuvel Pharmaceuticals' PE Ratio too high?
Clinuvel Pharmaceuticals' current PE Ratio of 17.30 is 65% below median its 10-year median of 48.81. Over the past 10 years, this metric has ranged from a low of 12.48 to a high of 144.38. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' PE Ratio compare to VRTX and REGN?
Clinuvel Pharmaceuticals' PE Ratio of 17.30 can be compared against companies in the Biotechnology industry. Historically, Clinuvel Pharmaceuticals' own PE Ratio has ranged from 12.48 to 144.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current PE Ratio is 17.30, which is 65% below median its own 10-year median of 48.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.93, compared to a current price of $7.30 — trading 43.5% below its estimated fair value. The current PE Ratio is 17.30, which is 65% below median its 10-year median of 48.81. Clinuvel Pharmaceuticals' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLY), the current PE Ratio is 17.30 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLY) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $7.30 is trading 43.5% below its estimated GF Value™ of $12.93.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLY:
PE Ratio: 17.30 (65% below median its 10-year median of 48.81)
GF Value™: $12.93 vs. price of $7.30 (43.5% below fair value)
No single metric tells the full story. See the CLVLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
84GF Score
Get the complete analysis for CLVLY
PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLY has been successfully added to your 
